These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3335813)

  • 1. Five-year immunologic memory in Swedish volunteers after oral cholera vaccination.
    Jertborn M; Svennerholm AM; Holmgren J
    J Infect Dis; 1988 Feb; 157(2):374-7. PubMed ID: 3335813
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunological memory after immunization with oral cholera B subunit--whole-cell vaccine in Swedish volunteers.
    Jertborn M; Svennerholm AM; Holmgren J
    Vaccine; 1994 Sep; 12(12):1078-82. PubMed ID: 7998416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection.
    Losonsky GA; Tacket CO; Wasserman SS; Kaper JB; Levine MM
    Infect Immun; 1993 Feb; 61(2):729-33. PubMed ID: 8423098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine.
    Svennerholm AM; Jertborn M; Gothefors L; Karim AM; Sack DA; Holmgren J
    J Infect Dis; 1984 Jun; 149(6):884-93. PubMed ID: 6736680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The immunology of cholera and the molecular biology of cholera toxin. Recent progress and future perspectives].
    Carrada-Bravo T
    Rev Alerg Mex; 1994; 41(3):69-76. PubMed ID: 9377108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic response to oral cholera vaccination in a crossover study: a novel placebo effect.
    Wasserman SS; Kotloff KL; Losonsky GA; Levine MM
    Am J Epidemiol; 1993 Dec; 138(11):988-93. PubMed ID: 8256784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brucella antibodies and oral cholera vaccination.
    Begue RE; Guillen A; Meza R
    Lancet; 1995 Jul; 346(8967):115-6. PubMed ID: 7603186
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunisation against cholera with a Ty21a-cholera hybrid.
    La Brooy JT; Forrest B; Bartholomeusz C
    Ann Sclavo Collana Monogr; 1986; 3(1-2):143-7. PubMed ID: 3426872
    [No Abstract]   [Full Text] [Related]  

  • 9. Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children.
    Hallander HO; Paniagua M; Espinoza F; Askelöf P; Corrales E; Ringman M; Storsaeter J
    Vaccine; 2002 Nov; 21(1-2):138-45. PubMed ID: 12443672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing the germfree mouse model for in vivo evaluation of oral Vibrio cholerae vaccine and vector strains.
    Crean TI; John M; Calderwood SB; Ryan ET
    Infect Immun; 2000 Feb; 68(2):977-81. PubMed ID: 10639476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of antibody responses and protective immunity in cholera vaccinated subjects.
    Chaicumpa W; Pacharaprakiti C; Plueksawan W; Atthasishtha N
    Southeast Asian J Trop Med Public Health; 1980 Mar; 11(1):58-66. PubMed ID: 7403955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactogenicity and immunogenicity of oral cholera vaccine in Thai volunteers.
    Migasena S; Pitisuttitham P; Supanaranond W; Desakorn V; Prayurahong B; Suntharasamai P
    Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):423-8. PubMed ID: 3217824
    [No Abstract]   [Full Text] [Related]  

  • 14. Cholera and the immune response.
    Holmgren J; Svennerholm AM
    Prog Allergy; 1983; 33():106-19. PubMed ID: 6338509
    [No Abstract]   [Full Text] [Related]  

  • 15. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
    Roland KL; Cloninger C; Kochi SK; Thomas LJ; Tinge SA; Rouskey C; Killeen KP
    Vaccine; 2007 Dec; 25(51):8574-84. PubMed ID: 18045752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reactogenicity and immunological effectiveness of an oral cholera chemical vaccine in a limited controlled experiment with human revaccination].
    Sumarokov AA; Ivanov NR; Lelikov VL; Dzhaparidze MN; Karaeva LT
    Zh Mikrobiol Epidemiol Immunobiol; 1978; (12):87-92. PubMed ID: 371293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgG and IgA subclass distribution of antitoxin antibody responses after oral cholera vaccination or cholera disease.
    Jertborn M; Svennerholm AM; Holmgren J
    Int Arch Allergy Appl Immunol; 1988; 85(3):358-63. PubMed ID: 3350611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of Vibrio cholerae toxoid on the levels of antibodies of the IgG, IgA and IgM classes in rabbits].
    Aleksandrowicz J; Kudelski Z
    Med Dosw Mikrobiol; 1986; 38(1):15-22. PubMed ID: 3713366
    [No Abstract]   [Full Text] [Related]  

  • 20. Diminished immunogenicity of a recombination-deficient derivative of Vibrio cholerae vaccine strain CVD103.
    Ketley JM; Kaper JB; Herrington DA; Losonsky G; Levine MM
    Infect Immun; 1990 May; 58(5):1481-4. PubMed ID: 2323828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.